Palma

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Retrieved on: 
Monday, November 22, 2021

Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.

Key Points: 
  • Vifor Pharma will acquire Sanifit, for the continued development and commercialization of SNF472, a novel, first-in-class inhibitor of vascular calcification for the treatment of CUA and PAD in patients with end-stage kidney disease.
  • Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the companys portfolio of innovative assets.
  • Todays exciting announcement helps us to build on our strong nephrology pipeline to help end-stage kidney disease patients globally, commented Abbas Hussain, Chief Executive Officer of Vifor Pharma Group.
  • We are excited to join forces with Vifor Pharma, which has a world-renowned commitment to patient focused cardio-renal therapies.

Universal Hotels chooses Magaluf for their new 'flagship' hotel

Retrieved on: 
Thursday, June 10, 2021

PALMA DE MALLORCA, Spain, June 10, 2021 /PRNewswire/ -- Universal Hotels has opened the Hotel Florida Magaluf in Majorca , a new concept of flagship hotel which, following a complete renovation, will be one aspect of the company's new brand structure.

Key Points: 
  • PALMA DE MALLORCA, Spain, June 10, 2021 /PRNewswire/ -- Universal Hotels has opened the Hotel Florida Magaluf in Majorca , a new concept of flagship hotel which, following a complete renovation, will be one aspect of the company's new brand structure.
  • The result is this completely renovated adults-only 4* hotel, inspired by the coolest hostelslocated in the main cities of the world, adapted to its Mediterranean setting.
  • As Yannik Erhart, CEO of Universal Hotels points out, "the new type of guest coming to Magaluf is looking for emotions, relaxation, entertainment, socialising, disconnection, yet at the same time they want to be connected with the world.
  • The spaces in Hotel Florida have been created based on the concept of "Social Living", designed to promote socialising, and creating unforgettable island holiday memories.

True North Advisory Expands with Veteran Tech Executives Andrew Miller and Dino Di Palma

Retrieved on: 
Thursday, June 3, 2021

WASHINGTON, June 3, 2021 /PRNewswire/ -- True North Advisory LLC, an innovative strategic advisory firm focused on helping technologyentrepreneurs and enterprises scale and grow their businesses, is expanding its own rankswith the addition of two new partners: Andrew M. Miller and Dino Di Palma.

Key Points: 
  • WASHINGTON, June 3, 2021 /PRNewswire/ -- True North Advisory LLC, an innovative strategic advisory firm focused on helping technologyentrepreneurs and enterprises scale and grow their businesses, is expanding its own rankswith the addition of two new partners: Andrew M. Miller and Dino Di Palma.
  • Both Miller and Di Palma are experienced tech executives with previous CEO experience.
  • True North founding partners Michael Tessler and Scott Hoffpauir launched BroadSoft in 1998, and Jim Tholen joined as CFO in 2007.
  • "I'm thrilled to become a True North Advisory partner," Di Palma concludes, "and eager to begin helping our clients develop winning strategies, overcome challenges and take advantage of emerging opportunities."

Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease

Retrieved on: 
Wednesday, February 10, 2021

Receiving Orphan Drug Designation may qualify Sanifit for a seven-year period of U.S. marketing exclusivity upon approval of SNF472, and a waiver of the Prescription Drug User Fee Act filing fees, subject to certain conditions.

Key Points: 
  • Receiving Orphan Drug Designation may qualify Sanifit for a seven-year period of U.S. marketing exclusivity upon approval of SNF472, and a waiver of the Prescription Drug User Fee Act filing fees, subject to certain conditions.
  • Joan Perell, Ph.D., Chief Executive Officer, of Sanifit, commented: Orphan drug designation from the FDA for PAD in ESKD is an important recognition for patients suffering from this condition and it further validates the potential of SNF472 in this indication.
  • We plan to advance clinical development of SNF472 to phase 3 in patients affected by this severe disease.
  • A Phase 3 pivotal study in calciphylaxis is currently underway and the Company is also pursuing peripheral arterial disease (PAD) in patients with end-stage kidney disease as a second indication for SNF472.

Palma Ceia SemiDesign Expands Asia Team, Names Bo Liu Senior Director of Engineering in China

Retrieved on: 
Tuesday, February 9, 2021

SANTA CLARA, Calif., Feb. 8, 2021 /PRNewswire/ -- Palma Ceia SemiDesign , a fabless semiconductor company specializing in wireless connectivity solutions, today announced Bo Liu has joined the company as senior director of Engineering in China.

Key Points: 
  • SANTA CLARA, Calif., Feb. 8, 2021 /PRNewswire/ -- Palma Ceia SemiDesign , a fabless semiconductor company specializing in wireless connectivity solutions, today announced Bo Liu has joined the company as senior director of Engineering in China.
  • Before joining Palma Ceia, Liuserved as senior director for wireless IC Design at Shanghai Artosyn Microelectronics.
  • "The developments Palma Ceia has made in Wi-Fi technology make this an exciting time to join the company," Liusaid about joining Palma Ceia.
  • Palma Ceia SemiDesign and the Palma Ceia SemiDesign logo are trademarks of Palma Ceia SemiDesign, a Cayman Islands corporation, and are protected by trademark laws of the United States and other jurisdictions.

Sanifit Appoints Adam Levy as Chief Financial Officer

Retrieved on: 
Thursday, August 20, 2020

Palma, Spain and San Diego, USA, 20 August 2020 Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced the appointment of Adam Levy as Chief Financial Officer, with immediate effect.

Key Points: 
  • Palma, Spain and San Diego, USA, 20 August 2020 Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced the appointment of Adam Levy as Chief Financial Officer, with immediate effect.
  • Mr. Levy was most recently with Brickell Biotech where he served as Chief Business Officer.
  • I am delighted to welcome Adam to the Sanifit team in his new role as CFO, an appointment which greatly strengthens our senior leadership team.
  • Adam holds a Bachelor of Science in Business Management and Marketing, Magna Cum Laude, from the Dyson School of Applied Economics and Management, Cornell University.

METRO Markets to acquire trivago’s Palma development center

Retrieved on: 
Friday, July 24, 2020

DSSELDORF, GERMANY July 24, 2020 trivago N.V. (NASDAQ: TRVG) announced today that METRO Markets GmbH, a subsidiary of Metro AG (FWB: B4B), based in Dsseldorf, will acquire its trivago subsidiary in Palma, Spain.

Key Points: 
  • DSSELDORF, GERMANY July 24, 2020 trivago N.V. (NASDAQ: TRVG) announced today that METRO Markets GmbH, a subsidiary of Metro AG (FWB: B4B), based in Dsseldorf, will acquire its trivago subsidiary in Palma, Spain.
  • Under the terms of the deal, METRO Markets will acquire 100% of the shares in trivago Spain SLU and take over the development center in Palma with approximately 60 employees.
  • The acquisition of the development center in Palma is a unique opportunity for us to increase our footprint by adding an experienced team with a similar tech culture to ours, added, Philipp Blome, CEO of METRO Markets.
  • METRO Markets GmbH is a wholly owned subsidiary of METRO AG, a leading international specialist for wholesale and food.

Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease

Retrieved on: 
Monday, July 20, 2020

The clinical program will consist of a cross-sectional study, planned to commence in Q3 2020, in a target population of ESKD patients with PAD.

Key Points: 
  • The clinical program will consist of a cross-sectional study, planned to commence in Q3 2020, in a target population of ESKD patients with PAD.
  • The clinical program was discussed with the FDA at a recent Type C meeting.
  • Given the prominent role of calcification in this disease, the clinical and preclinical data, we believe SNF472 has potential for clinical benefit.
  • There is currently no effective treatment for ESKD patients suffering from PAD, and prior clinical trials have excluded these patients.

First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis

Retrieved on: 
Thursday, February 13, 2020

The phase 3 study, known as CALCIPHYX, is designed to assess the effect of SNF472 when added to background care for the treatment of calciphylaxis patients with end stage kidney disease (ESKD) being treated with hemodialysis.

Key Points: 
  • The phase 3 study, known as CALCIPHYX, is designed to assess the effect of SNF472 when added to background care for the treatment of calciphylaxis patients with end stage kidney disease (ESKD) being treated with hemodialysis.
  • The endpoints of the trial will be: improvement in wound healing, assessed by the Bates-Jensen Wound Assessment Tool (BWAT) score; and pain, assessed by a Visual Analog Scale (VAS).
  • In a phase 2 study, SNF472 was associated with improved wound healing and pain in calciphylaxis patients and has been granted Orphan Drug Designation by the FDA and EMA.
  • A recent randomized controlled trial showed SNF472 also reduced progression of coronary calcification in patients with ESKD receiving hemodialysis.